Managing hyperkalemia in patients with heart failure on guideline-directed medical therapy: challenges and
Giorgio Gentile1,2, Jahid Hossain1,2, Erberto Carluccio3
1Department of Nephrology, Royal Cornwall Hospitals NHS Trust, Truro, UK.
Insights
Hyperkalemia management is crucial for heart failure patients on guideline-directed medical therapy. Novel approaches, including potassium binders, help maintain essential treatments and reduce cardiovascular risks.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Heart failure affects millions globally, posing significant healthcare burdens.
- Guideline-directed medical therapy (GDMT) includes beta-blockers, MRAs, ARNIs, and SGLT2 inhibitors.
- Hyperkalemia is a common complication of GDMT, often leading to dose reduction or discontinuation of vital medications.
Purpose of the Study:
- To explore novel strategies for managing hyperkalemia in heart failure patients.
- To emphasize the importance of maintaining GDMT despite hyperkalemia risks.
- To review current and emerging treatments for hyperkalemia in this population.
Main Methods:
- Review of current literature on heart failure pharmacotherapy and hyperkalemia management.
- Analysis of the impact of hyperkalemia on GDMT adherence and patient outcomes.
- Discussion of novel potassium-binding agents and monitoring strategies.
Main Results:
- Hyperkalemia frequently necessitates down-titration or cessation of GDMT, increasing cardiovascular event risk.
- Effective hyperkalemia management is essential for sustained GDMT benefits.
- New potassium binders (patiromer, sodium zirconium cyclosilicate) offer promising therapeutic options.
Conclusions:
- Optimizing hyperkalemia management is critical for heart failure care.
- Maintaining patients on GDMT through effective potassium control improves outcomes.
- Novel pharmacological agents and closer monitoring represent key advancements in managing hyperkalemia in heart failure.
Abstract:
Heart failure is a chronic and invalidating syndrome that affects tens of millions of people worldwide with significant socio-economic ramifications for the health care systems. Significant progress in the understanding of the pathophysiology of heart failure has allowed the gradual introduction of several drug classes for the management of such patients. Beta-blockers, mineralocorticoid receptor antagonists, angiotensin receptor neprilysin inhibitors, and sodium-glucose-cotransporter 2 inhibitors are all considered pillars of the guideline-directed medical therapy for heart failure. Despite remarkable improvements in the morbidity and mortality of heart failure, however, many patients still develop clinically significant hyperkalemia during combined treatment with those four pharmacological pillars. The consequence is often a down-titration or discontinuation of one or more crucial drugs, which in turns leads to a considerable increase in the risk of cardiovascular events, dialysis, and all-cause mortality. This paper will explore novel approaches for the management of hyperkalemia in heart failure, including closer monitoring of potassium levels, early review of drugs that might increase the risk of hyperkalemia, and pharmacological treatment of hyperkalemia, with a special emphasis on sodium-glucose-cotransporter 2 inhibitors and potassium-binding agents, including patiromer and sodium zirconium cyclosilicate.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: Diuretics
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...